



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

## BIB DATA SHEET

CONFIRMATION NO. 3995

SERIAL NUMBER	FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
10/502,180	07/21/2004 RULE	514	1612	OP/4-32328A

**APPLICANTS**

Romulus Kimbro Brazzell, Alpharetta, GA;  
 George N. Lambrou, Strasbourg, FRANCE;  
 Elisabeth Latour, Bartenheim-La Chaussee, FRANCE;  
 Anna Ottilecz, Basel, SWITZERLAND;  
 Jeanette Marjorie Wood, Benken, SWITZERLAND;

**\*\* CONTINUING DATA \*\*\*\*\***

This application is a 371 of PCT/EP03/00612 01/22/2003

**\*\* FOREIGN APPLICATIONS \*\*\*\*\***

UNITED KINGDOM 0201520.4 01/23/2002

**\*\* IF REQUIRED, FOREIGN FILING LICENSE GRANTED \*\***

Foreign Priority claimed	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Met after Allowance GH Initials	STATE OR COUNTRY	SHEETS DRAWINGS	TOTAL CLAIMS	INDEPENDENT CLAIMS
35 USC 119(a-d) conditions met	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		GA	0	12	2
Verified and Acknowledged Examiner's Signature	(GIGI GEORGIANA HUANG/					

**ADDRESS**

NOVARTIS  
 CORPORATE INTELLECTUAL PROPERTY  
 ONE HEALTH PLAZA 104/3  
 EAST HANOVER, NJ 07936-1080  
 UNITED STATES

**TITLE**

Pharmaceutical use of cox-2-inhibitors in angiogenesis-mediated ocular disorders

FILING FEE RECEIVED 920	FEES: Authority has been given in Paper No._____ to charge/credit DEPOSIT ACCOUNT No._____ for following:	<input type="checkbox"/> All Fees
		<input type="checkbox"/> 1.16 Fees (Filing)
		<input type="checkbox"/> 1.17 Fees (Processing Ext. of time)
		<input type="checkbox"/> 1.18 Fees (Issue)
		<input type="checkbox"/> Other _____
		<input type="checkbox"/> Credit _____